Abstract
DNase treatment for cystic fibrosis
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chernick, W. and Barbero, G. 1959. Composition of tracheobron chial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 24: 739–745.
Liao, T., Salnikow, J., Moore, S. and Stein, W. 1973. Biol Chem 248: 1489–1495.
Shak, S., Capon, D., Hellmiss, R., Marsters, S., and Baker, C. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U. S. A. 87: 9188–9192
Aitken, W., Burke, W., McDonald, G., Shak, S., Montgomery, A.B. and Smith, A. 1992. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 267: 1947–1951.
Hubbard, R., McElvaney, N., Birrer, P., Shak, S., Robinson, W., Jolley, C., Wu, M., Chernick, M., and Crystal, R. 1992. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New Eng. J. Med. 326: 812–815.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edgington, S. Nuclease Therapeutics in the Clinic. Nat Biotechnol 11, 580–582 (1993). https://doi.org/10.1038/nbt0593-580
Issue Date:
DOI: https://doi.org/10.1038/nbt0593-580